Gilead Sciences (GILD) Tops Q4 EPS by 19c, Offers Guidance
Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.90, $0.19 better than the analyst estimate of $1.71. Revenue for the quarter came in at $7.6 billion versus the consensus estimate of $7.16 billion.
GUIDANCE:
Gilead Sciences sees FY2025 EPS of $7.70-$8.10, versus the consensus of $7.54. Gilead Sciences sees FY2025 revenue of $28.2-28.6 billion, versus the consensus of $28 billion.
For the full-year 2025, Gilead expects:
(in millions, except per share amounts) |
| February 11, 2025 Guidance | |||||
| Low End |
| High End | ||||
Product sales |
| $ | 28,200 |
| $ | 28,600 | |
Product sales excluding Veklury |
| $ | 26,800 |
| $ | 27,200 | |
Veklury |
| $ | 1,400 |
| $ | 1,400 | |
Diluted EPS |
| $ | 5.95 |
| $ | 6.35 | |
Non-GAAP diluted EPS |
| $ | 7.70 |
| $ | 8.10 | |
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.